Is Pacific Edge a buy?

Is Pacific Edge a buy?

Of the analysts with advisory recommendations for Pacific Edge, there are there are currently 0 “buy” , 0 “hold” and 0 “sell” recommendations. The overall consensus recommendation for Pacific Edge is Buy.

Is Pacific Edge a good investment?

If you are looking for stocks with good return, Pacific Edge Limited can be a profitable investment option. With a 5-year investment, the revenue is expected to be around +131.6%.

What does Pacific Edge do?

Pacific Edge Limited, a cancer diagnostic company, researches, develops, and commercializes diagnostic and prognostic tools for the early detection and management of cancers in New Zealand, the United States, Australia, Singapore, and internationally.

What is a CX urine test?

Cxbladder is a suite of non-invasive, urine-based laboratory tests that are highly accurate, easy to use and clinically validated. Cxbladder tests measure the gene expression levels of five biomarkers in urine that effectively rule out or detect the presence of bladder cancer.

How much does cxbladder cost?

Additionally, at a cost of around $300 per test, the cost-effectiveness of Cxbladder compared with the currently recommended strategy has yet to be elucidated.

Is a hair test invasive?

Hair analysis is used for the detection of many therapeutic drugs and recreational drugs, including cocaine, heroin, benzodiazepines and amphetamines. Hair analysis is less invasive than a blood test, if not quite as universally applicable.

How accurate is cxbladder?

Cxbladder Monitor accurately rules out recurrent urothelial carcinoma. A recent study showed that Cxbladder Monitor, with a negative predictive value of 97% and a sensitivity of 93%, outperformed all other FDA-approved urine tests compared in this study for ruling out patients with a low risk of recur-rent disease.

What is a Urovysion fish test?

Urovysion™ fluorescence in situ hybridization (FISH) is a sensitive and specific test used to diagnose urothelial carcinoma in urine. It detects aneuploidy of chromosomes 3, 7 and 17, and loss of both 9p21 loci in malignant urothelial cells.

Can they find drugs in your blood?

Drugs in blood are typically detectable within minutes to hours, depending on the drug and the dose, versus one to several days in urine. Blood drug screen tests are performed on whole blood specimens using immunoassay screening with reflex to definitive testing.

Is cxbladder FDA approved?

These included the six FDA-approved tests (quantitative and qualitive NMP22, quantitative and qualitative BTA, FISH, and uCyt+) as well as a laboratory developed test that does not require FDA approval termed CxBladder.

How accurate is a fish test?

FISH is 42-83% sensitive for detecting pTa and pT1 lesions and 92-100% sensitive for pT2-4 invasive lesions in patients with known bladder cancer, while urine cytology yields sensitivities of 24-50% for pTa and pT1 lesions and 78-85% for pT2-4 invasive lesions.

Who is Pacific Edge Limited and what do they do?

Atlanta: American Cancer Society; 2019.OVERVIEW Pacific Edge Limited (NZX: PEB) is a New Zealand publicly listed, cancer diagnostic company specializing in the discovery and commercialization of diagnostic and prognostic tests for better detection and management of cancer.

Why is Pacific Edge listed on NZX Main Board?

Pacific Edge is listed on the NZX Main Board and provides an opportunity to invest into the fast growing cancer diagnostic market. Here you will find all the information you need to know about being a shareholder of Pacific Edge Limited. Latest news updates, announcements and calendar of events.

Where can I find Pacific Edge share price?

See the latest news and presentations, keep up to date with our newsletters and shareholder reports, find out when we are holding shareholder meetings and check up on our share price. Pacific Edge is a publicly listed company on the NZX: listed as PEB. If playback doesn’t begin shortly, try restarting your device.

When does Pacific Edge report its financial results?

Pacific Edge is pleased to present audited financial results for the 12 months to 31 March 2021. The company reports accelerating revenue growth in its key markets in FY21, despite the ongoing challenges of COVID-19 throughout the year. [read more]